IP Verse

Modulators Of Pharmacokinetic Properties Of Therapeutics - EP3150586

The patent EP3150586 was granted to Gilead Sciences on Jan 8, 2020. The application was originally filed on Feb 22, 2008 under application number EP16180589A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3150586

GILEAD SCIENCES
Application Number
EP16180589A
Filing Date
Feb 22, 2008
Status
Granted And Under Opposition
Dec 6, 2019
Grant Date
Jan 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEOct 8, 2020ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSOct 6, 2020EDERADMISSIBLE
STADA ARZNEIMITTELJan 10, 2020HAMM & WITTKOPPADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2008010921
OPPOSITIONEP1183026
OPPOSITIONWO2005039551
OPPOSITIONWO2008010921
OPPOSITIONWO9701349
SEARCHEP1183026
SEARCHWO2008010921
SEARCHWO9701349

Non-Patent Literature (NPL) Citations (48) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Carbonyl Protecting Groups", PROTECTING GROUPS, pages 155 - 184-
DESCRIPTION- "Carboxyl Protecting Groups", PROTECTING GROUPS, pages 118 - 154-
DESCRIPTION- "Diol Protecting Groups", PROTECTING GROUPS, pages 95 - 117-
DESCRIPTION- ERMOLIEFF J.; LIN X.; TANG J., BIOCHEMISTRY, (1997), vol. 36, page 12364-
DESCRIPTION- "Hydroxyl Protecting Groups", PROTECTING GROUPS, pages 21 - 94-
DESCRIPTION- J. AM. CHEM. SOC., (1960), vol. 82, page 5566-
DESCRIPTION- J. MED. CHEM., (1998), vol. 41, no. 4, pages 602 - 617-
DESCRIPTION- J. ORG. CHEM., (1996), vol. 61, pages 444 - 450-
DESCRIPTION- JURIMA-ROMET ET AL., DRUG METAB. DISPOS., (1994), vol. 22, pages 849 - 857-
DESCRIPTION- LEEMAN, T. ET AL., LIFE SCI, (1992), vol. 52, pages 29 - 34-
DESCRIPTION- LING, K.-H.J. ET AL., DRUG METAB. DISPOS., (1995), vol. 23, pages 631 - 636-
DESCRIPTION- M.V. TOTH; G.R.MARSHALL, INT.I. PEPTIDE PROTEIN RES., (1990), vol. 36, page 544-
DESCRIPTION- M.V. TOTH; G.R.MARSHALL, INT. T. PEPTIDE PROTEIN RES., (1990), vol. 36, page 544-
DESCRIPTION- "Protecting Groups: An Overview", PROTECTING GROUPS, pages 1 - 20-
DESCRIPTION- SYNTHESIS, (1976), page 823-
DESCRIPTION- TETRAHEDRON, (1997), vol. 53, page 4769-
DESCRIPTION- The Chemistry of Heterocyclic Compounds, A Series of Monographs, JOHN WILEY & SONS, (1950), vol. 13, 14,-
DESCRIPTION- T. MED. CHEM., (1993), vol. 36, page 1384-
DESCRIPTION- T. MED. CHEM., (1998), vol. 41, page 602-
DESCRIPTION- T. ORG. CHEM, (1987), vol. 52, page 3759-
DESCRIPTION- T. ORG. CHEM., (1994), vol. 59, page 1937-
DESCRIPTION- T. ORG. CHEM., (1996), vol. 61, page 444-
DESCRIPTION- WEISLOW OS; KISER R; FINE DL; BADER J; SHOEMAKER RH; BOYD MR, T. NATL. CANCER INST., (1989), vol. 81, page 577-
OPPOSITION- Amonymous, "Scientific Discussion on Viread", EMEA, (2005), pages 1 - 43, URL: www.ema. europa .eu, XP055742815-
OPPOSITION- Anonymous, "EVOTAZ 300 mg/150 mg film-coated tablets, SUMMARY OF PRODUCT CHARACTERISTICS", Bristol-Myers Squibb Pharma EEIG, pages 1 - 58-
OPPOSITION- Anonymous, "Genvoya 150 mg/150 mg/200 mg/'lO mg film-coated tablets, SUMMARY OF PRODUCT CHARACTERISTICS", Gilead Sciences International Ltd., pages 1 - 46-
OPPOSITION- Anonymous, "Hepsera 10 mg tablets SUMMARY OF PRODUCT CHARACTERISTICS", Gilead Sciences International Limited, pages 1 - 30-
OPPOSITION- Anonymous, "PREZISTAâ„¢", PREZISTAâ„¢* (Tibotec, Inc.) Summary of Product Characteristics,, (20060600), pages 1 - 41, URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppINo=021976, XP055383901-
OPPOSITION- Anonymous, "REZOLSTA 800 mg/150 mg film-coated tablets, SUMMARY OF PRODUCT CHARACTERISTICS", Janssen-Cilag International NV,, pages 1 - 48-
OPPOSITION- Anonymous, "Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets, SUMMARY OF PRODUCT CHARACTERISTICS", Gilead Sciences International Ltd, pages 1 - 46-
OPPOSITION- Anonymous, "Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets, SUMMARY OF PRODUCT CHARACTERISTICS", Janssen-Cilag International NV, pages 1 - 50-
OPPOSITION- Anonymous, "Tybost 150 mg film-coated tablets, SUMMARY OF PRODUCT CHARACTERISTICS", Gilead Sciences Ireland UC, pages 1 - 41-
OPPOSITION- Dale J Kempf; Et Al, "ABT-538 Is A Potent Inhibitor of Human Immunodeficiency Virus Protease and Has High Oral Bioavailability in Humans", Proc. Natl. Acad. Sci. USA, (19950000), vol. 92, pages 2484 - 2488, XP055377097-
OPPOSITION- Gilead Sciences International Ltd.,, "Tybost: International non-proprietary name: Cobicistat", EMA/CHMP/609914/2013; Assessment report, (20130725), pages 1 - 86, XP002732922-
OPPOSITION- KEMPF D J; ET AL, "Pharmacokinetic Enhancement of Inhibitors of the Human Immunodeficiency Virus Protease by Coadministration with Ritonavir", Antimicrobial Agents and Chemotherapy, (19970000), vol. 41, no. 3, pages 654 - 660, XP002480911-
OPPOSITION- KUMAR G N; ET AL, "Cytochrome P450-Mediated Metabolism of the HIV-1 Protease Inhibitor Ritonavir (ABT-538) in Human Liver Microsomes", The Journal or Pharmacology and Experimental Therapeutics, (19960000), vol. 277, no. 1, pages 423 - 431, XP008024470-
OPPOSITION- Robert E Babine and Steven L Bender, "Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design", Chemical Reviews,, (19970000), vol. 97, pages 1359 - 1472, XP007918342-
OPPOSITION- Maria Almira Correia; Paul R Ortiz De Monteflano, "Inhibition of Cytochrome P450 Enzymes", CYTOCHROME P450: STRUCTURE, MECHANISM, AND BIOCHEMISTRY, 3rd edition,, Plenum Publishers, (20050000), pages 247 - 322, doi:10.1007/0-387-27447-2_7, XP055266135
OPPOSITION- Pedro Cahn, Omar Sued, "Raltegravir: a new antiretroviral class for salvage therapy", The Lancet, (20070414), vol. 369, no. 9569, pages 1235 - 1236, XP022027818
OPPOSITION- HOSUR et al., "Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease", J. Am. Chem, Soc., (19940000), vol. 116, pages 847 - 855, XP055381323
OPPOSITION- Paul A J Janssen; Paul J Lewi; Eddy Arnold; Frits Daeyaert; Marc de Jonge; Jan Heeres; Luc Koymans; Maarten Vinkers; Jerome Guillemont; Elisabeth Pasquier; Mike Kukla; Don Ludovici; Koen Andries; Marie-Pierre de Bethune; Rudi Pauwels; Kalyan Das; Art D Clark; Yulia Volovik Frenkel; Stephen H Hughes; Bart Medaer; Fons De Knaep; Hilde Bohets; Fred De Clerck; Ann Lampo; Peter Williams; and Paul Stoffels, "In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6- dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)", JOURNAL OF MEDICINAL CHEMISTRY,, (20050000), vol. 48, pages 1901 - 1909, XP002460263
OPPOSITION- Lianhong Xu; Hongtao Liu; Bernard P Murray; Christian Callebaut; Melody S Lee; Allen Hong; Robert G Strickley; Luong K Tsai; Kirsten M Stray; Yujin Wang; Gerry R Rhodes and Manoj C Desai, "Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer", ACS MEDICINAL CHEMISTRY LETTERS,, (20100000), vol. 1, doi:10.1021/ml1000257, pages 209 - 213, XP009156835
OPPOSITION- EKROOS MARIKA; SJ\GREN T, "Structural basis for ligand promiscuity in cytochrome P450 3A4", Proc.Natl. Acad. Sci., (20060000), vol. 103, no. 37, pages 13682 - 13687, XP002435643
OPPOSITION- F. P. Guengerich, "A malleable catalyst dominates the metabolism of drugs", Proceedings of the National Academy of Sciences, (20060912), vol. 103, no. 37, pages 13565 - 13566, XP055742778
OPPOSITION- Irina F. Sevrioukova, Thomas L. Poulos, "Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir", PNAS, (20100000), vol. 107, no. 43, pages 18422 - 18427, XP055742787
OPPOSITION- YANO J K; ET AL, "The Structure of Human Microsomal Cytochrome P450 3A4 determined by X-ray Crystallography to 2.05-Ã… Resolution", J. Biol. Chem., (20040000), vol. 279, no. 37, doi:10.1074/jbc.C400293200, pages 38091 - 38094, XP002347677
OPPOSITION- Catia Marzolini; Sara Gibbons; Saye Khoo; David Back, "Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY,, (20160000), vol. 71, pages 1755 - 1758, XP055413065
OPPOSITION- BIRKUS G; ET AL, "Cathepsin a is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs", Antimicrobial Agents and Chemotherapy, (20070200), vol. 51, no. 2, pages 543 - 550, XP002605879

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents